Aegerion’s Jeffrey Bloss Joins Tarveda as Chief Medical Officer

Jeffrey Bloss has been appointed chief medical officer of Tarveda Therapeutics. Bloss comes to Watertown, MA-based Tarveda from Aegerion Pharmaceuticals, where he was chief medical officer and senior vice president, medical affairs. His experience includes senior roles at Astellas Pharma (OTCMKTS: [[ticker:ALPMY]]), GlaxoSmithKline (NYSE: [[ticker:GSK]]), Genentech, and Eli Lilly (NYSE: [[ticker:LLY]]). Last year, Tarveda raised $30 million to finance clinical trials for its experimental cancer drugs.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.